JWH-007

JWH-007 is a synthetic cannabinoid in the naphthoylindole family. It is structurally related to JWH-018, but has an additional methyl group at the 2-position of the indole ring. It was developed as part of early research into cannabinoid receptor ligands and has been identified in synthetic cannabinoid reference databases. Its receptor-binding properties are documented, while human clinical information is sparse.

Chemistry and relationship to JWH-018

JWH-007 is (2-methyl-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone. It contains a naphthoylindole core with a pentyl chain attached to the indole nitrogen and a methyl substituent at the 2-position. JWH-018 lacks this additional methyl group, making JWH-007 a close structural analogue rather than another name for the same substance.

UNODC lists JWH-007 as a synthetic cannabinoid receptor agonist and provides its full chemical identity and molecular formula (UNODC substance record: JWH-007).

Pharmacology

Published receptor-binding data report Ki values of approximately 9.5 nM at CB₁ and 2.9 nM at CB₂. These measurements indicate affinity for both receptor subtypes, with a modest preference for CB₂ in that assay. Binding values can vary across experimental systems and do not, by themselves, establish functional efficacy or human potency (Synthetic cannabinoid receptor-binding data).

JWH-007 belongs to the early naphthoylindole group synthesised by John W. Huffman’s research team. This family helped establish the structure–activity relationships later used to understand many first-generation synthetic cannabinoids (Walsh and colleagues, 2020).

Reported effects

There is little reliable human reporting that isolates JWH-007 from other synthetic cannabinoids. Its receptor affinity is consistent with cannabinoid activity, but there are no controlled human studies defining a characteristic subjective experience or clinical duration.

Clinical effects described for JWH-018 and other naphthoylindoles include altered perception, sedation, agitation, anxiety and, in severe cases, seizures. These observations concern related compounds, not a confirmed pattern of symptoms for JWH-007.

Toxicity and research limitations

No well-characterised clinical case series or human metabolism study specific to JWH-007 was identified in the sources reviewed here. Its acute toxic range, dependence potential and long-term effects remain uncertain.

Because JWH-007 differs from JWH-018 by a small but chemically meaningful substitution, the pharmacology and toxicology of one compound should not be assigned automatically to the other.

Related compounds

JWH-007 is related to JWH-018, JWH-019 and other naphthoylindoles. It is the 2-methyl analogue of JWH-018.